Inventor · disambiguated record
Chi-Chung Li
Also filed as: LI CHI-CHUNG
4 granted patents·12 pending applications·30 citations·filing 2007–2025
72Inventor score
Top patents by PatentIndex Score
16 records- 0188US8071121B2Dispersions of microemulsions in hydrogels for drug deliveryCHAUHAN ANUJ·Filed 2007·Granted Dec 6, 2011·21 cites·6 claims
- 0283US11466094B2Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodiesGENENTECH INC·Filed 2017·Granted Oct 11, 2022·8 cites·82 claims
- 0381US2024376223A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2024·Application pending·0 cites
- 0479US2024132613A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2023·Application pending·0 cites
- 0577US12351643B2Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodiesGENENTECH INC·Filed 2021·Granted Jul 8, 2025·1 cites·80 claims
- 0676US2023242659A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2023·Application pending·0 cites
- 0770US2025171552A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2025·Application pending·0 cites
- 0867US2024270909A1Multimodulus silicone resins based on thiol-ene-epoxy chemistriesMETA PLATFORMS TECH LLC·Filed 2024·Application pending·0 cites
- 0955US2022380466A1Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2022·Application pending·0 cites
- 1051US12492261B2Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodiesGENENTECH INC·Filed 2021·Granted Dec 9, 2025·0 cites·42 claims
- 1151US2024043553A1Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomideGENENTECH INC·Filed 2023·Application pending·0 cites
- 1249US2023190932A1Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomideGENENTECH INC·Filed 2022·Application pending·0 cites
- 1346US2018346586A1Methods of treating cancer using anti-ox40 antibodiesGENENTECH INC·Filed 2018·Application pending·0 cites
- 1444US2018256711A1Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonistsGENENTECH INC·Filed 2017·Application pending·0 cites
- 1540US2016355597A1Methods of treating cancer using anti-ox40 antibodiesGENENTECH INC·Filed 2016·Application pending·0 cites
- 1640US2017000885A1Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonistsGENENTECH INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chi-Chung Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →